Currently out of the existing stock ratings of Jonathan Wolleben, 209 are a BUY (99.52%), 1 are a HOLD (0.48%).

Jonathan Wolleben

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Wolleben, currently employed at JMP, carries an average stock price target met ratio of 34.63% that have a potential upside of 56.42% achieved within 223 days.

Jonathan Wolleben’s has documented 408 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MDGL, Madrigal Pharmaceuticals at 20-Aug-2025.

Wall Street Analyst Jonathan Wolleben

Analyst best performing recommendations are on RYTM (RHYTHM PHARMACEUTICALS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 6/26/2025. The price target of $84 was fulfilled within 13 days with a profit of $22.55 (36.7%) receiving and performance score of 28.23.

Average potential price target upside

of $143.72 (84.09%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $37.14 (124%) on MIRM (MIRUM PHARMACEUTICALS).
of $21.86 (92.42%) on CRNX (CRINETICS PHARMACEUTICALS).

ALT Altimmune CLSD Clearside Biomedical CRNX Crinetics Pharmaceuticals DBVT DBV Technologies LRMR Larimar Therapeutics OCUL Ocular Therapeutix PRQR ProQR Therapeutics BV BCRX BioCryst Pharmaceuticals RLYB Rallybio Corp PHVS Pharvaris BV MDGL Madrigal Pharmaceuticals AURA Aura Biosciences PTGX Protagonist Therapeutics ALLK Allakos MIRM Mirum Pharmaceuticals SPRB Spruce Biosciences RYTM Rhythm Pharmaceuticals SVRA Savara GPCR Structure Therapeutics American Depositary Shares SGMT Sagimet Biosciences Series A Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Mayank Mamtani (B. RILEY)